The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

Yue Zhi Lee; Hsing Yu Hsu; Cheng Wei Yang; Yi Ling Lin; Sui Yuan Chang; Ruey Bing Yang; Jian Jong Liang; Tai Ling Chao; Chun Che Liao; Han Chieh Kao; Jang Yang Chang; Huey Kang Sytwu; Chiung Tong Chen; Shiow Ju Lee

doi:10.3390/pharmaceutics14071511

The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

Yue Zhi Lee, Hsing Yu Hsu, Cheng Wei Yang, Yi Ling Lin, Sui Yuan Chang, Ruey Bing Yang, Jian Jong Liang, Tai Ling Chao, Chun Che Liao, Han Chieh Kao, Jang Yang Chang, Huey Kang Sytwu, Chiung Tong Chen, Shiow Ju Lee

研究成果: 雜誌貢獻 › 文章 › 同行評審

1 引文斯高帕斯（Scopus）

摘要

Ciclesonide is an inhaled corticosteroid used to treat asthma and has been repurposed as a treatment for mildly ill COVID-19 patients, but its precise mechanism of action is unclear. Herein, we report that ciclesonide blocks the coronavirus-induced production of the cytokines IL-6, IL-8, and MCP-1 by increasing IκBα protein levels and significantly decreasing p65 nuclear translocation. Furthermore, we found that the combination of ciclesonide and dbq33b, a potent tylophorine-based coronavirus inhibitor that affects coronavirus-induced NF-κB activation a little, additively and synergistically decreased coronavirus-induced IL-6, IL-8, and MCP-1 cytokine levels, and synergistically inhibited the replication of both HCoV-OC43 and SARS-CoV-2. Collectively, the combination of ciclesonide and dbq33b merits consideration as a treatment for COVID-19 patients who may otherwise be overwhelmed by high viral loads and an NF-κB-mediated cytokine storm.

原文	英語
文章編號	1511
期刊	Pharmaceutics
卷	14
發行號	7
DOIs	https://doi.org/10.3390/pharmaceutics14071511
出版狀態	已發佈 - 7月 2022
對外發佈	是

ASJC Scopus subject areas

藥學科學

存取文件

10.3390/pharmaceutics14071511

其它文件與鏈接

Link to publication in Scopus

引用此

Lee, Y. Z., Hsu, H. Y., Yang, C. W., Lin, Y. L., Chang, S. Y., Yang, R. B., Liang, J. J., Chao, T. L., Liao, C. C., Kao, H. C., Chang, J. Y., Sytwu, H. K., Chen, C. T., & Lee, S. J. (2022). The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b. Pharmaceutics, 14(7), [1511]. https://doi.org/10.3390/pharmaceutics14071511

Lee, YZ, Hsu, HY, Yang, CW, Lin, YL, Chang, SY, Yang, RB, Liang, JJ, Chao, TL, Liao, CC, Kao, HC, Chang, JY, Sytwu, HK, Chen, CT & Lee, SJ 2022, 'The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b', Pharmaceutics, 卷 14, 編號 7, 1511. https://doi.org/10.3390/pharmaceutics14071511

@article{421add872cdb4cbe929513e01b64cd38,

title = "The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b",

abstract = "Ciclesonide is an inhaled corticosteroid used to treat asthma and has been repurposed as a treatment for mildly ill COVID-19 patients, but its precise mechanism of action is unclear. Herein, we report that ciclesonide blocks the coronavirus-induced production of the cytokines IL-6, IL-8, and MCP-1 by increasing IκBα protein levels and significantly decreasing p65 nuclear translocation. Furthermore, we found that the combination of ciclesonide and dbq33b, a potent tylophorine-based coronavirus inhibitor that affects coronavirus-induced NF-κB activation a little, additively and synergistically decreased coronavirus-induced IL-6, IL-8, and MCP-1 cytokine levels, and synergistically inhibited the replication of both HCoV-OC43 and SARS-CoV-2. Collectively, the combination of ciclesonide and dbq33b merits consideration as a treatment for COVID-19 patients who may otherwise be overwhelmed by high viral loads and an NF-κB-mediated cytokine storm.",

keywords = "ciclesonide, COVID-19, cytokine, IL-6, IL-8, MCP-1, MCP-3, OC43, SARS-CoV-2, tylophorine",

author = "Lee, {Yue Zhi} and Hsu, {Hsing Yu} and Yang, {Cheng Wei} and Lin, {Yi Ling} and Chang, {Sui Yuan} and Yang, {Ruey Bing} and Liang, {Jian Jong} and Chao, {Tai Ling} and Liao, {Chun Che} and Kao, {Han Chieh} and Chang, {Jang Yang} and Sytwu, {Huey Kang} and Chen, {Chiung Tong} and Lee, {Shiow Ju}",

note = "Funding Information: This work was funded by the National Health Research Institutes, Taiwan; Academia Sinica (AS-CFII-108-102); the Ministry of Science and Technology, Taiwan, (MOST 109-2327-B-400-003; MOST 109-3114-Y-001-001; MOST 109-2811-B-400-518; MOST 109-2327-B-002-009; MOST 110-2811-B-400-522); and the Ministry of Health and Welfare, Taiwan, for an emergent grant of COVID-19. Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = jul,

doi = "10.3390/pharmaceutics14071511",

language = "English",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "7",

}

TY - JOUR

T1 - The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

AU - Lee, Yue Zhi

AU - Hsu, Hsing Yu

AU - Yang, Cheng Wei

AU - Lin, Yi Ling

AU - Chang, Sui Yuan

AU - Yang, Ruey Bing

AU - Liang, Jian Jong

AU - Chao, Tai Ling

AU - Liao, Chun Che

AU - Kao, Han Chieh

AU - Chang, Jang Yang

AU - Sytwu, Huey Kang

AU - Chen, Chiung Tong

AU - Lee, Shiow Ju

N1 - Funding Information: This work was funded by the National Health Research Institutes, Taiwan; Academia Sinica (AS-CFII-108-102); the Ministry of Science and Technology, Taiwan, (MOST 109-2327-B-400-003; MOST 109-3114-Y-001-001; MOST 109-2811-B-400-518; MOST 109-2327-B-002-009; MOST 110-2811-B-400-522); and the Ministry of Health and Welfare, Taiwan, for an emergent grant of COVID-19. Publisher Copyright: © 2022 by the authors.

PY - 2022/7

Y1 - 2022/7

N2 - Ciclesonide is an inhaled corticosteroid used to treat asthma and has been repurposed as a treatment for mildly ill COVID-19 patients, but its precise mechanism of action is unclear. Herein, we report that ciclesonide blocks the coronavirus-induced production of the cytokines IL-6, IL-8, and MCP-1 by increasing IκBα protein levels and significantly decreasing p65 nuclear translocation. Furthermore, we found that the combination of ciclesonide and dbq33b, a potent tylophorine-based coronavirus inhibitor that affects coronavirus-induced NF-κB activation a little, additively and synergistically decreased coronavirus-induced IL-6, IL-8, and MCP-1 cytokine levels, and synergistically inhibited the replication of both HCoV-OC43 and SARS-CoV-2. Collectively, the combination of ciclesonide and dbq33b merits consideration as a treatment for COVID-19 patients who may otherwise be overwhelmed by high viral loads and an NF-κB-mediated cytokine storm.

AB - Ciclesonide is an inhaled corticosteroid used to treat asthma and has been repurposed as a treatment for mildly ill COVID-19 patients, but its precise mechanism of action is unclear. Herein, we report that ciclesonide blocks the coronavirus-induced production of the cytokines IL-6, IL-8, and MCP-1 by increasing IκBα protein levels and significantly decreasing p65 nuclear translocation. Furthermore, we found that the combination of ciclesonide and dbq33b, a potent tylophorine-based coronavirus inhibitor that affects coronavirus-induced NF-κB activation a little, additively and synergistically decreased coronavirus-induced IL-6, IL-8, and MCP-1 cytokine levels, and synergistically inhibited the replication of both HCoV-OC43 and SARS-CoV-2. Collectively, the combination of ciclesonide and dbq33b merits consideration as a treatment for COVID-19 patients who may otherwise be overwhelmed by high viral loads and an NF-κB-mediated cytokine storm.

KW - ciclesonide

KW - COVID-19

KW - cytokine

KW - IL-6

KW - IL-8

KW - MCP-1

KW - MCP-3

KW - OC43

KW - SARS-CoV-2

KW - tylophorine

UR - http://www.scopus.com/inward/record.url?scp=85136376382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85136376382&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics14071511

DO - 10.3390/pharmaceutics14071511

M3 - Article

AN - SCOPUS:85136376382

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 7

M1 - 1511

ER -

The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

摘要

ASJC Scopus subject areas

存取文件

其它文件與鏈接

指紋

引用此